CellSource Co Ltd
TSE:4880

Watchlist Manager
CellSource Co Ltd Logo
CellSource Co Ltd
TSE:4880
Watchlist
Price: 1 117 JPY -2.53% Market Closed
Market Cap: 22.1B JPY
Have any thoughts about
CellSource Co Ltd?
Write Note

CellSource Co Ltd
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

CellSource Co Ltd
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
CellSource Co Ltd
TSE:4880
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CMIC Holdings Co Ltd
TSE:2309
Cash Paid for Dividends
-ÂĄ883m
CAGR 3-Years
-15%
CAGR 5-Years
-11%
CAGR 10-Years
-3%
C
Chiome Bioscience Inc
TSE:4583
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Precision System Science Co Ltd
TSE:7707
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Medinet Co Ltd
TSE:2370
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WDB coco Co Ltd
TSE:7079
Cash Paid for Dividends
-ÂĄ98.6m
CAGR 3-Years
-8%
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

CellSource Co Ltd
Glance View

Market Cap
22.1B JPY
Industry
Life Sciences Tools & Services

CellSource Co., Ltd. engages in regenerative medicine related business. The company is headquartered in Shibuya-Ku, Tokyo-To and currently employs 90 full-time employees. The company went IPO on 2019-10-28. The firm operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.

Intrinsic Value
958.43 JPY
Overvaluation 14%
Intrinsic Value
Price

See Also

Back to Top